Benralizumab
Phase 3Active 0 watching 0 views this week📈 Rising
77
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedIndication / Disease
Severe Eosinophilic Asthma
Conditions
Severe Eosinophilic Asthma
Trial Timeline
Feb 28, 2024 → Dec 31, 2026
NCT ID
NCT06465485About Benralizumab
Benralizumab is a phase 3 stage product being developed by AstraZeneca for Severe Eosinophilic Asthma. The current trial status is active. This product is registered under clinical trial identifier NCT06465485. Target conditions include Severe Eosinophilic Asthma.
Hype Score Breakdown
Clinical
27
Activity
18
Company
10
Novelty
9
Community
10
Clinical Trials (18)
| NCT ID | Phase | Status |
|---|---|---|
| NCT07444567 | Phase 3 | Recruiting |
| NCT07214753 | Pre-clinical | Recruiting |
| NCT06512883 | Phase 3 | Recruiting |
| NCT06465485 | Phase 3 | Active |
| NCT05273359 | Phase 2 | UNKNOWN |
| NCT05384938 | Approved | Completed |
| NCT05932849 | Pre-clinical | Completed |
| NCT04305405 | Phase 3 | Completed |
| NCT04102800 | Approved | Completed |
| NCT03928262 | Phase 1 | Completed |
| NCT03557307 | Phase 3 | Completed |
| NCT03327701 | Phase 3 | UNKNOWN |
| NCT03010436 | Phase 2 | UNKNOWN |
| NCT02918071 | Phase 3 | Completed |
| NCT02869438 | Phase 3 | Completed |
| NCT02821416 | Phase 3 | Completed |
| NCT02417961 | Phase 3 | Completed |
| NCT02130882 | Phase 2/3 | UNKNOWN |
Competing Products
20 competing products in Severe Eosinophilic Asthma